胸腔内化疗联合热疗治疗恶性胸腔积液临床研究

目的研究胸腔内化疗联合热疗对恶性胸腔积液的近期疗效及毒副作用。方法将60例恶性胸腔积液患者随机分为2组：对照组30例接受单纯胸腔内化疗，给予胸腔内中心静脉置管抽液后注入化疗药物；研究组30例接受胸腔内置管抽液化疗联合热疗。2组均为1次／周，共4次，评价2组患者的近期疗效及毒副作用。结果研究组生活质量改善的有效率（93．33％）高于对照组（66．67％）（P〈0．01）。研究组胸腔积液控制的有效率（86．67％）高于对照组（63.33％）（P〈0．05）。2组消化道反应及血液学毒性之间差异无统计学意义（P〉0．05）。结论胸腔内化疗联合热疗治疗恶性胸腔积液较单纯胸腔内化疗疗效高，耐受性艮好。

Intracavitary perfusing chemotherapy combined with WBH for patients with malignant hydrothorax

Objective To study the short-term effect and toxicity of intracavitary chemotherapy for patients with malignant hydrothorax. Methods Sixty patients with malignant hydrothorax were divided into two groups. The control group （ n = 30） only received intracavitary chemotherapy, while the other the study group （n = 30） received intracavitary chemotherapy com- bined with whole body hyperthermia （WBH）. Every patient received the treatment once a week and four times in total. Results The overall response rate in improving of quality of life in the study group （93.33%） was obviously higher than that in the control group （66.67%） （P〈0.01）. The overall response rate in pleural effusion controlling in the study group （86.67 % ） was obviously higher than that in the control group （63.33 % ） （P 〈 0.05）. Digestive reactions and hematotoxici- ty showed no significant difference in both groups （P 〉 0. 05 ）. Conclusion Intracavitary chemotherapy combined with the WBH for patients with malignant hydrothorax is more efficient and well tolerated.